Showing results (281-290 of 313) with videos related to

Sort By:
Pageof 32
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaHagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Cancer|October 15, 2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsElias Jabbour, Stefan Faderl, Koji Sasaki, et al.
Blood|August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
The Lancet. Oncology|October 19, 2012
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyHagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, et al.
American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Blood|July 10, 2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapyFarhad Ravandi, Jeffrey L Jorgensen, Deborah A Thomas, et al.
Pageof 32